![Drug resistance profile of Mycobacterium tuberculosis isolates from patients referred to tuberculosis reference laboratory in Kosovo Bajrami R, Mulliqi G, Kurti A, Lila G, Raka L - Int J Mycobacteriol Drug resistance profile of Mycobacterium tuberculosis isolates from patients referred to tuberculosis reference laboratory in Kosovo Bajrami R, Mulliqi G, Kurti A, Lila G, Raka L - Int J Mycobacteriol](https://www.ijmyco.org/articles/2019/8/1/images/IntJMycobacteriol_2019_8_1_22_253953_t1.jpg)
Drug resistance profile of Mycobacterium tuberculosis isolates from patients referred to tuberculosis reference laboratory in Kosovo Bajrami R, Mulliqi G, Kurti A, Lila G, Raka L - Int J Mycobacteriol
![Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges | Genome Medicine | Full Text Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges | Genome Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13073-019-0660-8/MediaObjects/13073_2019_660_Fig1_HTML.png)
Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges | Genome Medicine | Full Text
![PDF) Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia PDF) Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia](https://www.researchgate.net/profile/Yanina-Balabanova/publication/8049803/figure/tbl2/AS:601770535436329@1520484684869/significant-differences-in-rates-of-primary-resistance-to-first-line-drugs-among-civilian_Q320.jpg)
PDF) Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia
![Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120429908-gr6.jpg)
Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect
![PDF) Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia PDF) Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia](https://www.researchgate.net/profile/Yanina-Balabanova/publication/8049803/figure/tbl1/AS:601770535448609@1520484684833/Prevalence-of-drug-resistance-in-new-and-previously-treated-civilian-cases-n-309-in_Q320.jpg)
PDF) Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia
![Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120429908-gr2.jpg)
Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect
![A polymeric approach toward resistance-resistant antimicrobial agent with dual-selective mechanisms of action | Science Advances A polymeric approach toward resistance-resistant antimicrobial agent with dual-selective mechanisms of action | Science Advances](https://www.science.org/cms/asset/94653487-094b-442f-9ce9-de0993f8a4be/abc9917-f1.gif)
A polymeric approach toward resistance-resistant antimicrobial agent with dual-selective mechanisms of action | Science Advances
![Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120429908-gr1.jpg)
Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect
![Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120429908-grabsf1.jpg)
Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib - ScienceDirect
![Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance | BMC Infectious Diseases | Full Text Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance | BMC Infectious Diseases | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12879-019-4069-1/MediaObjects/12879_2019_4069_Fig1_HTML.png)